These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19679052)

  • 21. Focus on Barrett's esophagus and esophageal adenocarcinoma.
    Paulson TG; Reid BJ
    Cancer Cell; 2004 Jul; 6(1):11-6. PubMed ID: 15261138
    [No Abstract]   [Full Text] [Related]  

  • 22. Gastroesophageal reflux disease and Barrett's esophagus.
    Anand O; Wani S; Sharma P
    Endoscopy; 2008 Feb; 40(2):126-30. PubMed ID: 18058620
    [No Abstract]   [Full Text] [Related]  

  • 23. Gastroesophageal reflux and cancer.
    Turcotte S; Duranceau A
    Thorac Surg Clin; 2005 Aug; 15(3):341-52. PubMed ID: 16104125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.
    Casson AG; Zheng Z; Evans SC; Geldenhuys L; van Zanten SV; Veugelers PJ; Porter GA; Guernsey DL
    Cancer; 2005 Aug; 104(4):730-9. PubMed ID: 15971196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper gastrointestinal tumors.
    Lambert R
    Endoscopy; 2006 Feb; 38(2):133-6. PubMed ID: 16479419
    [No Abstract]   [Full Text] [Related]  

  • 26. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.
    Li H; Zhang L; Lou H; Ding I; Kim S; Wang L; Huang J; Di Sant'Agnese PA; Lei JY
    Am J Clin Pathol; 2005 Aug; 124(2):282-7. PubMed ID: 16040301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA ploidy, P53 expression, and cellular proliferation in normal epithelium and squamous dysplasia of non-cancerous and cancerous human oesophagi.
    Itakura Y; Sasano F; Date F; Kato K; Sekine H; Mori S; Nagura H
    Anticancer Res; 1996; 16(1):201-8. PubMed ID: 8615609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.
    Bailey T; Biddlestone L; Shepherd N; Barr H; Warner P; Jankowski J
    Am J Pathol; 1998 Jan; 152(1):135-44. PubMed ID: 9422531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus.
    Sihvo EI; Ruohtula T; Auvinen MI; Koivistoinen A; Harjula AL; Salo JA
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1952-7. PubMed ID: 14688711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
    Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
    Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.
    Parenti A; Leo G; Porzionato A; Zaninotto G; Rosato A; Ninfo V
    Hum Pathol; 2006 Jan; 37(1):16-22. PubMed ID: 16360411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
    Goldblum JR; Lauwers GY
    Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
    Hermann B; Li Y; Ray MB; Wo JM; Martin RC
    Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Markers of malignant potential and clinical management of dysplasia in Barrett esophagus].
    Roth JA; Hölscher AH; Schneider PM
    Chirurg; 1994 Feb; 65(2):96-101. PubMed ID: 8162821
    [No Abstract]   [Full Text] [Related]  

  • 38. [Barrett's esophagus and primary adenocarcinoma of the esophagus].
    Seco JL; Velasco A; Hilario E; Corrales JI; Alvarez JL; Ojeda C; Santamaría JL
    Rev Esp Enferm Apar Dig; 1981 May; 59(5):617-26. PubMed ID: 7291673
    [No Abstract]   [Full Text] [Related]  

  • 39. [Role of miRNA in the diagnosis, prognosis and treatment of esophageal cancer].
    Cao XF; Li SQ
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):161-4. PubMed ID: 21575511
    [No Abstract]   [Full Text] [Related]  

  • 40. [A study on cyclooxygenase-2 protein expression in esophageal carcinoma and premalignant lesions].
    Wang L; Zhang W; Wang W
    Zhonghua Zhong Liu Za Zhi; 2001 Jan; 23(1):14-6. PubMed ID: 11783060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.